Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Apr 14, 2023; 29(14): 2188-2201
Published online Apr 14, 2023. doi: 10.3748/wjg.v29.i14.2188
Table 2 Cancers and mortality in different groups

HBV
HCV
NBNC
P value
Total cases1064507391
Female239 (22.5)234 (46.2)158 (40.4)< 0.027
Follow years before enrollment-2.65 ± 3.98-2.78 ± 5.56-3.30 ± 6.25< 0.001 (3 & 1, 3 & 2)
Cancers, pre-enrollment
HCC150 (14.1)42 (8.3)20 (5.1)< 0.001
Non-HCC cancer36 (3.4)30 (5.9)39 (10.0)< 0.001
Colon cancer9 (0.8)3 (0.6)6 (1.5)NS
Breast cancer1 (0.1)9 (1.8)17 (4.3)< 0.0011
Hematology cancers3 (0.3)4 (0.8)2 (0.5)NS
Follow years before enrollment-2.76 ± 4.55-3.57 ± 5.18-3.22 ± 4.40NS
Cancers, post-enrollment
HCC43 (4.0)19 (3.7) 5 (1.3)0.033
Non-HCC tumor21 (2.2)14 (2.8)12 (3.1)NS
Colon cancer2 (0.1)3 (0.6)1 (0.3)NS
Breast cancer2 (0.2)0 (0.0)1 (0.3)NS
Hematology cancers6 (0.6)0 (0.0)1 (0.5)NS
Prostate cancer 2 (0.1)1 (0.2)1 (0.3)NS
Follow years after enrollment2.43 ± 1.862.51 ± 1.862.25 ± 2.00NS
Mortality total72 (6.8)41 (8.1)21 (5.4)NS
HCC35 (3.3)13 (2.6)4 (1.0)20.057
Non-HCC cancers16 (1.5)8 (1.6)7 (1.8)2NS
Liver disease6 (0.6)7 (1.4)6 (1.5)NS
Non-liver disease15 (1.4)13 (2.6)4 (1.0)NS
Follow years after enrollment 2.59 ± 1.962.69 ± 1.992.00 ± 1.87NS